Evidence map›Paper›PMID 28102015›Full record

Trial reportThe Prostate2017

Circulating Antioxidant Levels and Risk of Prostate Cancer by TMPRSS2:ERG.

Rebecca E Graff, Gregory Judson, Thomas U Ahearn, Michelangelo Fiorentino, Massimo Loda, Edward L Giovannucci, Lorelei A Mucci, Andreas Pettersson

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Prostate, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Selenium for preventing cancer.The Cochrane database of systematic reviews · 2018
    Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Rebecca E GraffDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Gregory JudsonDepartment of Medicine, University of California San Francisco, San Francisco, California.
Thomas U AhearnDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Michelangelo FiorentinoDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Massimo LodaCenter for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Edward L GiovannucciDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Lorelei A MucciDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Andreas PetterssonDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Harvard University · USUniversity of California, San Francisco · USBrigham and Women's Hospital · USDana-Farber Cancer Institute · US

Funding

Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ROSNER, BERNARD A · 2000 to 2019
$77.8M
Tumor and Circulating Markers as Links Between Obesity and Lethal Prostate CanceP50CA090381 · NCI · DANA-FARBER CANCER INSTITUTE · PI KANTOFF, PHILIP W · 2002 to 2017
$36.2M
Training Program in Cancer EpidemiologyT32CA009001 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI A. Heather Eliassen, Meir Stampfer · 1985 to 2026
$17.3M
Cancer Epidemiology Cohort in Male Health ProfessionalsUM1CA167552 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI WILLETT, WALTER C. · 2012 to 2016
$11.5M
Training in Molecular& Genetic Epidemiology of CancerR25CA112355 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WITTE, JOHN S. · 2005 to 2018
$6.5M
Sex-Hormones and the TMPRSS2: ERG Fusion in Prostate Cancer ProgressionR01CA136578 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI MUCCI, LORELEI · 2009 to 2013
$1.7M
NCI NIH HHS P01 CA087969NCI NIH HHS P50 CA090381NCI NIH HHS R01 CA136578NCI NIH HHS R25 CA112355NCI NIH HHS T32 CA009001NCI NIH HHS UM1 CA167552
6 · The paper itself

Abstract

backgroundFew studies have considered etiological differences across molecular subtypes of prostate cancer, despite potential to improve opportunities for precision prevention of a disease for which modifiable risk factors have remained elusive. Factors that lead to DNA double-strand breaks, such as oxidative stress, may promote the formation of the TMPRSS2:ERG gene fusion in prostate cancer. We tested the hypothesis that increasing levels of pre-diagnostic circulating antioxidants, which may reduce oxidative stress, are associated with lower risk of developing TMPRSS2:ERG positive prostate cancer.

methodsWe conducted a nested case-control study, including 370 cases and 2,470 controls, to evaluate associations between pre-diagnostic α- and β-carotene, α- and γ-tocopherol, β-cryptoxanthin, lutein, lycopene, retinol, and selenium with the risk of prostate cancer by ERG protein expression status (a marker of TMPRSS2:ERG). Multivariable unconditional polytomous logistic regression was used to calculate odds ratios and 95% confidence intervals.

resultsWe did not find any of the antioxidants to be significantly associated with the risk of prostate cancer according to ERG status.

conclusionsThe results do not support the hypothesis that circulating pre-diagnostic antioxidant levels protect against developing TMPRSS2:ERG positive prostate cancer. Additional studies are needed to explore mechanisms for the development of TMPRSS2:ERG positive disease. Prostate 77: 647-653, 2017. © 2017 Wiley Periodicals, Inc.

Indexed as

AdultAgedAged, 80 and overAntioxidantsBiomarkers, TumorCase-Control StudiesDouble-Blind MethodFollow-Up StudiesHumansMaleMiddle AgedProspective StudiesProstatic NeoplasmsRisk FactorsSerine EndopeptidasesTranscriptional Regulator ERGAntioxidantsBiomarkers, TumorERG protein, humanSerine EndopeptidasesTMPRSS2 protein, humanTranscriptional Regulator ERGbiomarkersepidemiologymolecular subtypes

Identifiers

PMID28102015
PMCPMC5354965
OpenAlexW2579627752

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.